Delivery Order SPE2DB22D1106-SPE2DB25FDSG4

Award Date 12/30/24
Potential Completion Date 12/31/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for the pharmaceutical product WEGOVY 0.5 MG/0.5 ML PEN 0.5ML, with a ceiling value of $20,696.16 and a period of performance through December 24, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,583.28 delivery order is for the medication WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The contract has a firm fixed price and an ultimate completion date of November 14, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,638.00, is a delivery order to provide the drug WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The contract has a firm fixed price pricing type and an ultimate completion date of December 18, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,500.59 firm fixed-price delivery order is for the pharmaceutical product WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of December 17, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a $12,270.42 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of the prescription medication WEGOVY 2.4 MG/0.75 ML PEN 0.75ML, with a period of performance through August 30, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, is for the supply of the medication WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract, valued at $1,097.08, is a delivery order issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of April 25, 2024. The contract is a firm fixed-price arrangement, without any set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract...
This is a $2,516.46 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of the prescription drug WEGOVY 2.4 MG/0.75 ML PEN 0.75ML, with a completion date of June 27, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order valued at $2,374.92 for the supply of the drug WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The firm-fixed-price contract, valued at $4,749.84, has an ultimate completion date of October 10, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999, for delivering a range of medical commodities to support military...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract, valued at $35,003.75, is for the delivery of the prescription drug WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, which has a ceiling value of up to $999,999,999.00 and runs through December 31, 2025. The IDC...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB25FDSG4
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,742.00, is for the supply of the drug WEGOVY 1 MG/0.5 ML PEN 0.5ML. This is a firm-fixed-price delivery order without any set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

Generated 3/31/25, 9:33 AM